FRANKLIN LAKES, N.J., April 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer. In March 2014, CareFusion Corp., which was acquired by BD in 2015, had acquired a non-controlling, minority stake in CME.
“Our relationship with BD has been very successful over the past two years, and this is the next logical step to elevate our infusion technologies,” said Swi Barak, founder of CME. “This transaction will create new opportunities for our people and our technology that we wouldn’t have been able to achieve alone.”
The acquisition of CME expands BD’s infusion portfolio to include ambulatory, home and specialty acute care infusion pumps. CME designs, manufactures and markets a range of infusion and syringe pumps as well as related accessories and disposable administration sets for both homecare and hospital settings. CME infusion pumps are known for their compact and highly portable design, making them ideal for specialty applications such as IV and epidural anesthesia and pain management, hospital and home nutrition, among others.
“The integration of CME’s technology into BD will strengthen our strategy of reinventing medication management across the health care continuum,” said Mike Garrison, vice president and general manager of worldwide Infusion Solutions for BD. “The acquisition of CME advances our mission to provide efficient end-to-end IV safety solutions across a broad journey of care.”
This transaction completes the acquisition of the remaining 60 percent of CME. CareFusion had initially acquired a non-controlling 40 percent stake of CME in 2014. Additional terms of the transaction were not disclosed.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.